REG - Diaceutics PLC - Director / PDMR Shareholding

DiaceuticsAnnouncement

23/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW5550Pa&default-theme=true

RNS Number : 5550P  Diaceutics PLC  23 May 2024

 

Director / PDMR Shareholding - NED Purchase of Shares

 

 

Belfast and London, 23 May 2024 - Diaceutics PLC (AIM: DXRX) ("Diaceutics" or
the "Company"), a leading technology and solutions provider to the pharma and
biotech industry announces that on 22 May 2024, Graham Paterson, a
Non-Executive Director of Diaceutics, purchased 39,934 ordinary shares of
£0.002 each in the Company ("Ordinary Shares") at a price of £1.2889 per
Ordinary Share. As a result of the purchase, Graham Paterson's shareholding
in Diaceutics is 73,498 Ordinary Shares representing approximately 0.09% of
the Company's issued share capital.

 

 

Enquiries:

 

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network®.

 

 

 

 

 

 

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Graham Paterson
 2   Reason for notification
 a.  Position/Status                                              Non-Executive Director
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics PLC
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.002 each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Purchase
 c.  Price(s) and volume(s)                                                    Share purchase:
                                                                               Price(s)     Volume(s)
     £1.2889                                                                   39,934

 d.  Date of the transaction                                      22 May 2024
 e.  Place of the transaction                                     AIM Market of the London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHQKBBNDBKBOPB